Surgery Partners jumps 47.6% after probes into $23.50-per-share buyout

What happened

Surgery Partners (SGRY) rose 47.6% on October 26, 2026, after shareholder-law firms opened probes into HealthSpan Partners’ proposed $23.50-per-share all-cash buyout. The surge followed notices from firms including Schall, Brown & Schwartz LLP and Halper Sadeh LLC inviting investors to participate in potential fraud or fairness inquiries, and reports by GuruFocus, PRNewsWire and Business Wire outlining the investigations. Trading far outpaced the wider market and healthcare peers, indicating the takeover chatter and attendant legal scrutiny were the likely drivers of the session’s move.

How big was the move

The stock’s close at $23.25 represented a one-day rise of 47.6% and a five-session gain of 58.1%. Volume was 33.4 times its 20-day average, making this a highly active session. The move measured 7.8 times a typical daily move for this stock and was 47.7 percentage points better than the healthcare sector median. By contrast, the S&P 500 rose 0.7% on the day and fell 0.2% over the last five sessions, underscoring how company-specific the rally was.

The technical picture

Surgery Partners traded well above its short- and long-term averages, at 56.9% above its 20-day moving average, 61.5% above its 50-day moving average and 60.5% above its 200-day moving average. It had been above the 200-day average for 10 consecutive trading days and sat 0.8% below its 52-week high. Momentum readings showed strength: the Relative Strength Index (14 days) was 87, a level often called overbought, while 60-day volatility was 96% annualized, the highest reading of the past five years. Nonetheless, the 50-day average is below the 200-day average, a sign of a weak longer-term trend, and the stock’s beta of 1.20 indicates it tends to move more than the market.

Fundamentals and valuation

Over the four quarters through June 30, 2026, Surgery Partners recorded revenue of $3.37 billion, which grew 4.0% from a year earlier and compares with revenue growth of 5.4% one quarter earlier. Diluted earnings per share for that period were $-0.69, and gross margin was 21.4% versus 23.7% a year earlier. Operating margin stood at 11.9%, modestly above the prior-year 11.2%, and free-cash-flow margin was 5.6%. The company reported net debt of 4.0 times EBITDA, and share count over one year increased by 1.5%.

On valuation measures provided, price to forward earnings was 57.4 times expected earnings and free-cash-flow yield was 9.1%. Those metrics contrast with PromtFinance scores that rank the stock high on Value at 92 but weak on Growth at 33 and on Stability at 26. The mix of a high valuation metric and relatively weak growth and stability scores helps explain why some investors and advisers might question whether the buyout price fully reflects underlying business risks.

Earnings and analyst expectations

Surgery Partners last reported on August 10, 2026, posting earnings per share of $0.10 against $0.06 expected, a result 72.6% above estimates and the second consecutive quarter beating estimates. The company’s average surprise over the last four reports was 14.9% above estimates, though the typical two-day reaction after recent reports was a fall of 2.7%. The next scheduled report is November 9, 2026.

Analysts covering the name number 22, with a consensus rating of Buy and 64% of ratings at Buy or Strong Buy. The consensus price target is $18.00, which is 22.6% below the closing price on October 26, 2026. That disparity between the street target and the session close highlights the degree to which deal-related dynamics and the legal notices have altered near-term market pricing for the stock.

What to watch

• November 9, 2026: scheduled next earnings report
• Status and filings from law firms Schall, Brown & Schwartz LLP and Halper Sadeh LLC regarding the investigations
• Any statements or disclosure from Surgery Partners or HealthSpan Partners about deal terms, fiduciary processes or competing proposals
• Changes in trading volume or price action versus the S&P 500 and the healthcare sector median over coming sessions
• Regulatory filings that could disclose additional details about the $23.50 per share transaction or potential challenges